Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TAM-ADaCT

Financiado

A Novel Antibody-Drug Conjugate for Targeting Tumor-Associated Macrophages in So...

A Novel Antibody-Drug Conjugate for Targeting Tumor-Associated Macrophages in Solid Tumors "The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion in the Tumor Microenvironment (TME). With a primary focus on breast cancer and solid tumor... ver más

31/08/2025

ZELULA BIOPHARMA

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ZELULA BIOPHARMA Fabricación de productos farmacéuticos de base sociedad limitada

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-07

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ZELULA BIOPHARMA

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AGAINST Achieving the golden Grail in solid tumor treatment 150K€ Cerrado

FJC2020-043641-I Deciphering the immunosuppressive tumor microenvironment of... Cerrado

FJC2019-041213-I Novel immunotherapy for cancer targeting macrophages 50K€ Cerrado

PID2021-125212OA-I00 MECANOBIOLOGIA DE LA RESPUESTA INMUNE EN CANCER 157K€ Cerrado

PID2019-105404RB-I00 GENERATION DE NUEVAS HERRAMIENTAS IMMUNOTERAPEUTICAS PARA EL... 127K€ Cerrado

RTC-2016-5118-1 Inmunoterapia del cáncer mediante anticuerpos coestimuladore... 313K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2024-02-07
Fecha Fin: 2025-08-31

Líder del proyecto

ZELULA BIOPHARMA Fabricación de productos farmacéuticos de base sociedad limitada

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion in the Tumor Microenvironment (TME). With a primary focus on breast cancer and solid tumors, this initiative represents a paradigm shift in cancer therapeutics. The presence of Tumor-Associated Macrophages (TAMs) in the TME has been identified as a significant factor in tumor progression and immune evasion. Our proposed ADC will directly target these macrophages, effectively depleting them and thereby creating a more favorable environment for tumor eradication. The primary objectives of this project are as follows: 1. To synthesise and optimise ADCs for specific targeting and depletion of TAMs in the TME. 2. To demonstrate the efficacy of the ADC in preclinical models, establishing its potential for human application. 3. To perform a thorough ""freedom to operate"" analysis, ensuring that the ADC technology does not infringe upon existing intellectual property rights. 4. To establish a detailed plan for the commercial development of this ADC, outlining steps for regulatory approval, manufacturing scalability, and market entry. By achieving these objectives, we aim to propel this project from the conceptual stage to a viable, commercialisable medical solution. The successful implementation of this ADC has the potential to revolutionise cancer treatment, offering a targeted approach that could significantly improve patient outcomes. The support of ERC Proof of Concept Grant will be pivotal in transitioning this transformative technology from the laboratory to the marketplace, ultimately changing the landscape of cancer therapeutics. The strategic positioning of Zelula Biopharma (Host Institution) as a spin-off of CIC bioGUNE adds substantial value to this project, leveraging a unique blend of resources, academic research excellence and entrepreneurial agility to accelerate the transition from lab to market."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores